Tactiva Therapeutics is a development-stage immuno-oncology company based in Buffalo, NY focused on adoptive T-cell therapy. Its core product is the dual enhanced adoptive cell therapy (DEACT™) platform, which consists of engineered CD4/CD8 cells that generate a durable supply of CD4 cells with direct anti-tumor activity and sustained helper function to CD8 TCR-transduced effector T cells. The company intends to use the $35M Series A financing to advance clinical development of DEACT for multiple myeloma and several solid tumor indications. Tactiva closed the first tranche of the Series A. The round was led by Panacea Healthcare Partners with participation from Vi Ventures and Efung Capital. The company has also received funding and collaboration support from the UB Center for Advanced Technology in Big Data and Health Sciences and partners with the Buffalo Institute for Genomics and Data Analytics; Matthew Colpoys is CEO and Tactiva operates from UB’s New York State Center of Excellence on the Buffalo Niagara Medical Campus.

Total raised

$35M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2018